$559 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | SPDR SERIES TRUSTput | $43,509,000 | -23.9% | 5,566 | -30.4% | 7.39% | -33.8% | |
| NVS | Sell | NOVARTIS A Gsponsored adr | $15,960,000 | -15.8% | 200,000 | -21.6% | 2.71% | -26.8% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $12,913,000 | -9.7% | 383,047 | -20.7% | 2.19% | -21.5% |
| SHPG | Sell | SHIRE PLCsponsored adr | $11,321,000 | -26.6% | 68,500 | -68.1% | 1.92% | -36.2% |
| Sell | CELGENE CORPcall | $6,771,000 | -54.5% | 500 | -58.3% | 1.15% | -60.5% | |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $4,884,000 | +185.4% | 2,200,000 | -24.1% | 0.83% | +148.5% |
| IMMU | Sell | IMMUNOMEDICS INC | $4,857,000 | -21.0% | 550,000 | -42.1% | 0.82% | -31.4% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $4,486,000 | -37.3% | 161,617 | -36.7% | 0.76% | -45.5% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $4,028,000 | +13.0% | 400,000 | -20.0% | 0.68% | -1.9% |
| GLYC | Sell | GLYCOMIMETICS INC | $3,580,000 | -15.0% | 320,796 | -58.6% | 0.61% | -26.2% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $3,118,000 | -46.2% | 257,665 | -7.7% | 0.53% | -53.2% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $2,852,000 | -56.1% | 62,000 | -58.7% | 0.48% | -61.8% |
| GNCA | Sell | GENOCEA BIOSCIENCES INC | $2,558,000 | -35.0% | 490,000 | -24.2% | 0.44% | -43.4% |
| AKAOQ | Sell | ACHAOGEN INC | $1,630,000 | -67.7% | 75,000 | -62.5% | 0.28% | -71.9% |
| SMMT | Sell | SUMMIT THERAPEUTICS PLCspons ads | $1,561,000 | -20.6% | 142,018 | -3.7% | 0.26% | -31.2% |
| XLRN | Sell | ACCELERON PHARMA INC | $1,064,000 | -59.8% | 35,000 | -65.0% | 0.18% | -65.0% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $718,000 | -45.3% | 228,029 | -30.5% | 0.12% | -52.3% |
| CATB | Sell | CATABASIS PHARMACEUTICALS IN | $409,000 | -34.1% | 288,030 | -25.8% | 0.07% | -43.0% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $398,000 | -88.8% | 5,000 | -90.0% | 0.07% | -90.2% |
| PTN | Sell | PALATIN TECHNOLOGIES INC | $203,000 | -78.7% | 470,983 | -83.8% | 0.03% | -81.7% |
| ATHX | Exit | ATHERSYS INC | $0 | – | -773 | -100.0% | 0.00% | – |
| TRVN | Exit | TREVENA INC | $0 | – | -116,800 | -100.0% | -0.08% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -25,500 | -100.0% | -0.14% | – |
| GNMX | Exit | AEVI GENOMIC MEDICINE INC | $0 | – | -405,000 | -100.0% | -0.15% | – |
| RPRX | Exit | REPROS THERAPEUTICS INC | $0 | – | -778,800 | -100.0% | -0.18% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -100,000 | -100.0% | -0.21% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -242,000 | -100.0% | -0.23% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -60,000 | -100.0% | -0.25% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -40,000 | -100.0% | -0.28% | – |
| AAP | Exit | ADVANCE AUTO PARTS INC | $0 | – | -11,237 | -100.0% | -0.33% | – |
| ZYNE | Exit | ZYNERBA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.39% | – |
| TBT | Exit | PROSHARES TR | $0 | – | -55,950 | -100.0% | -0.43% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -108,023 | -100.0% | -0.46% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -140,000 | -100.0% | -0.53% | – |
| SBUX | Exit | STARBUCKS CORP | $0 | – | -46,631 | -100.0% | -0.53% | – |
| SLB | Exit | SCHLUMBERGER LTD | $0 | – | -34,911 | -100.0% | -0.53% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -35,000 | -100.0% | -0.54% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -45,000 | -100.0% | -0.67% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.73% | – |
| Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -1,500 | -100.0% | -0.93% | – | |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $0 | – | -172,000 | -100.0% | -1.08% | – |
| Exit | ISHARES TRput | $0 | – | -500 | -100.0% | -1.36% | – | |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -480,000 | -100.0% | -1.39% | – |
| Exit | NEUROCRINE BIOSCIENCES INCput | $0 | – | -1,500 | -100.0% | -1.57% | – | |
| Exit | SPDR S&P 500 ETF TRput | $0 | – | -1,000 | -100.0% | -4.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.